Korea S.E.
06:00:00 2024-04-28 pm EDT
5-day change
1st Jan Change
8,750
KRW
+0.57%
+0.57%
-14.80%
Dongwha Pharm.Co.,Ltd's Equity Buyback announced on July 20, 2017 has closed with 100,000 shares, representing 0.36% for KRW 875.76 million.
The company closed its plan on September 21, 2017.
Cong Ty Co Phan Tscare announced that it has received KRW 37.442505601 billion in funding from Dongwha Pharm.Co.,Ltd
Dec. 06
CI
Oncocross Co., Ltd. announced that it has received KRW 15.00002592 billion in funding from InterVest Co., Ltd., Dongwha Pharm.Co.,Ltd and other investors
23-10-26
CI
Oncocross Co., Ltd. announced that it expects to receive KRW 15.00002592 billion in funding from InterVest Co., Ltd., Dongwha Pharm.Co.,Ltd and other investors.
23-09-24
CI
Dongwha Pharm.Co.,Ltd signed an agreement to acquire 51% stake in TRUNGSONCARE CO., LTD for $30 million.
23-08-03
CI
Cong Ty Co Phan Tscare announced that it expects to receive KRW 39.115606503 billion in funding from Dongwha Pharm.Co.,Ltd
23-08-02
CI
Dongwha Pharm.Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-15
CI
Dongwha Pharm.Co.,Ltd agreed to acquire additional 11.18% stake in MEDYSSEY Co.,Ltd for KRW 4 billion.
20-10-04
CI
Dongwha Pharm.Co.,Ltd completed the acquisition of 53.3% stake in MEDYSSEY Co.,Ltd from Jongwook Jang, Min-kyung Jang, Ho-jeong Kim, Ji-won Jang and Seon-ok Kim.
20-09-23
CI
Dongwha Pharm.Co.,Ltd agreed to acquire 53.3% stake in MEDYSSEY Co.,Ltd from Jongwook Jang, Min-kyung Jang, Ho-jeong Kim, Ji-won Jang and Seon-ok Kim for KRW 19.6 billion.
20-07-23
CI
Philosys Co., Ltd. announced that it has received KRW 4 billion in funding from Dongwha Pharm.Co.,Ltd
18-04-25
CI
Philosys Co., Ltd. announced that it expects to receive KRW 4 billion in funding from Dongwha Pharm.Co.,Ltd
18-04-22
CI
Tranche Update on Dongwha Pharm.Co.,Ltd's Equity Buyback Plan announced on July 20, 2017.
17-09-24
CI
Dongwha Pharm.Co.,Ltd's Equity Buyback announced on July 20, 2017 has closed with 100,000 shares, representing 0.36% for KRW 875.76 million.
17-09-20
CI
Dongwha Pharm.Co.,Ltd announces an Equity Buyback for 100,000 shares.
17-07-20
CI
Dongwha Pharm.Co.,Ltd authorizes a Buyback Plan.
17-07-19
CI
Tranche Update on Dongwha Pharm Co.,Ltd.'s Equity Buyback Plan announced on January 30, 2015.
15-04-23
CI
Tranche Update on Dongwha Pharm Co.,Ltd.'s Equity Buyback Plan announced on January 30, 2015.
15-04-23
CI
Dongwha Pharm Co.,Ltd.’s Equity Buyback announced on January 30, 2015 has closed with 320,000 shares, representing 1.15% for KRW 2,349.54 million.
15-04-21
CI
Dongwha Pharm Co.,Ltd. announces an Equity Buyback for 320,000 shares.
15-01-29
CI
Dongwha Pharm Co.,Ltd. authorizes a Buyback Plan.
15-01-29
CI
Dong Wha Pharmaceuticals and Kyung Hee University Sign Technology Transfer Agreement
14-08-18
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
DONGWHA PHARM.CO., LTD is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products consist of ethical drugs, including digestive system remedies, antibiotics, cardiovascular and metabolic disease treatments, non steroidal anti-inflammatory drugs, respiratory remedies, muscle relaxants, nervous system remedies, dermatological remedies and urinary system remedies, and over-the-counter (OTC) drugs, including cold remedies, dental remedies, dermatological remedies, hepatic protectors, nutrients, tonics, topical analgesics, anti-smoking agents and others. It also provides medicine raw materials, health food and drinks, as well as cosmetics. The Company distributes its products within domestic market and to overseas markets.
More about the company
1st Jan change
Capi.
-14.80% 176M +19.27% 43.75B +27.47% 22.06B +15.67% 14.46B +12.33% 13.62B +38.36% 11.61B -9.54% 6.9B -0.05% 6.79B -8.87% 5.73B +9.64% 5.32B
Generic Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
DONGWHA PHARM.CO.,LTD 
